Allogene Intangible Assets from 2010 to 2026
| ALLO Stock | USD 1.80 0.18 11.11% |
Intangible Assets | First Reported 2010-12-31 | Previous Quarter 135.9 K | Current Value 129.1 K | Quarterly Volatility 312.7 K |
Check Allogene Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allogene Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.2 M, Interest Expense of 197.7 K or Selling General Administrative of 62.4 M, as well as many indicators such as Price To Sales Ratio of 17.8 K, Dividend Yield of 0.0 or PTB Ratio of 0.93. Allogene financial statements analysis is a perfect complement when working with Allogene Therapeutics Valuation or Volatility modules.
Allogene | Intangible Assets | Build AI portfolio with Allogene Stock |
Evaluating Allogene Therapeutics's Intangible Assets across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Allogene Therapeutics's fundamental strength.
Latest Allogene Therapeutics' Intangible Assets Growth Pattern
Below is the plot of the Intangible Assets of Allogene Therapeutics over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. Allogene Therapeutics' Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Allogene Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Intangible Assets | 10 Years Trend |
|
Intangible Assets |
| Timeline |
Allogene Intangible Assets Regression Statistics
| Arithmetic Mean | 468,059 | |
| Geometric Mean | 348,355 | |
| Coefficient Of Variation | 66.80 | |
| Mean Deviation | 302,761 | |
| Median | 754,000 | |
| Standard Deviation | 312,674 | |
| Sample Variance | 97.8B | |
| Range | 624.9K | |
| R-Value | (0.87) | |
| Mean Square Error | 25.3B | |
| R-Squared | 0.76 | |
| Slope | (53,894) | |
| Total Sum of Squares | 1.6T |
Allogene Intangible Assets History
About Allogene Therapeutics Financial Statements
Allogene Therapeutics investors utilize fundamental indicators, such as Intangible Assets, to predict how Allogene Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Intangible Assets | 135.9 K | 129.1 K |
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allogene Stock
Moving against Allogene Stock
| 0.79 | OSE | OSE Pharma SA | PairCorr |
| 0.72 | RAC | Race Oncology | PairCorr |
| 0.62 | DRMA | Dermata Therapeutics | PairCorr |
| 0.48 | VCEL | Vericel Corp Ord | PairCorr |
| 0.45 | CDIOW | Cardio Diagnostics | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Allogene Therapeutics Correlation against competitors. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Biotechnology sector continue expanding? Could Allogene diversify its offerings? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Allogene Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Allogene Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Allogene Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Allogene Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.